Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats

Qi, Keke; Lv, Jiajia; Wu, Jie; Xu, Ziwei

doi:10.1186/s12876-017-0593-x

Cited by 10 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a potent regenerative agent, the R-spondin 1 protein (Rspo1) has been reported to promote repopulation of the mouse intestinal epithelium, resulting in the amelioration of inflammatory symptoms in not only DSS-induced experimental mice but also IL-10-deficient colitis model mice [51]. Porcine glucagon-like peptide-2 (pGLP-2) is expected to be a potentially effective agent against UC because of its therapeutic effect associated with increased crypt proliferation and the subsequent reduced production of inflammatory cytokines [52,53]. As therapeutic agents, the IJH-SONE68-derived EPSs are expected to have a protective effect on the colonic mucosa, with potent mitogenic activity in crypt cells.…”

Section: Discussionmentioning

confidence: 99%

The Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Ameliorates Inflammatory Responses in DSS–Induced Ulcerative Colitis

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an autoimmune disease characterized by chronic inflammation of the gastrointestinal tract. IBD includes Crohn’s disease (CD) and ulcerative colitis (UC). CD can occur in any part of the gastrointestinal tract, whereas UC mainly occurs in the colon and rectum. We previously demonstrated that a novel exopolysaccharide (EPS) produced by a plant-derived bacterium, Lactobacillus paracasei IJH-SONE68, prevents and improves the inflammation in contact dermatitis model mice via oral administration. To evaluate the preventive effect of the EPS against other inflammatory diseases, in the present study, we employed dextran sulfate sodium (DSS)-induced UC model mice. The stool consistency, hematochezia, and colonic atrophy of the mice were improved by the orally administered EPS. We also evaluated the cytokine transcription. Overexpression of the mouse macrophage inflammatory protein 2 mRNA in the colon as a functional homolog of human interleukin-8 was decreased by the orally administered EPS. However, the expression of interleukin-10, which is known as an anti-inflammatory cytokine, was stimulated in the EPS-administrated group. Based on these results, we conclude that the IJH-SONE68-derived EPS is a promising lead material for the development of drugs useful in treating inflammatory diseases such as UC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Ameliorates Inflammatory Responses in DSS–Induced Ulcerative Colitis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The mechanisms of flavonoids regulating the enteroendocrine system are as follows: flavonoids can stimulate the secretion of cholecystokinin (CCK), ghrelin, glucagon-like peptide (GLP-1), and glucagon-like peptide (GLP-2) [49][50][51][52]. GLP-1/2; exhibit considerable potential in treating IBD due to their ability to promote the restoration of the impaired epithelial barrier; regulate T lymphocyte differentiation and function; and modulate innate immune cells, such as macrophages and dendritic cells [53][54][55][56]. Ghrelin has also been shown to mitigate intestinal inflammation in colitis mice [57].…”

Section: The Modulation Of the Enteroendocrine Systemmentioning

confidence: 99%

Quercetin: A Potential Drug Candidate for Inflammatory Bowel Disease

Li,

Gao

2024

Quercetin - Effects on Human Health [Working Title]

View full text Add to dashboard Cite

Over the past decades, the incidence rate of inflammatory bowel disease (IBD) has significantly risen all over the world. Most of the patients with IBD suffer from severe symptoms and complications. Being an autoimmune disease, recent research indicates that certain factors, such as environmental changes, disturbances in intestinal microbiota, abnormal immune responses, and genetic susceptibility, play a role in the pathogenesis of IBD. Nevertheless, the precise cause of IBD remains ambiguous. Therefore, there is no known cure for IBD. Moreover, traditional medications have troublesome side effects. For these reasons, some phytochemicals with more tolerance and less adverse effects capture the interest of medical scientists. Flavonoid, a natural anti-inflammatory compound, has recently been validated for its efficacy in IBD treatment. Among the extensive flavonoid family, comprising over 5000 members, quercetin has emerged as a promising drug candidate for treating IBD, supported by substantial preclinical evidence. Currently, quercetin participates in regulating IBD through several pathways, such as antioxidant properties, improvement of the intestinal barrier, modulation of the microbiota, immune response, and regulation of the enteroendocrine system in the gut. In brief, quercetin, a natural compound with anti-inflammatory activity, demonstrates a huge potential as a candidate drug for IBD treatment.

show abstract

“…Yang et al [98] investigated the anti-inflammatory activity of peptide-10, which has a 10 times longer half-period than teduglutide, the half-life of which is 3-5 h. They discovered that peptide-10 exhibited stronger anti-inflammatory effects than with teduglutide in mice colitis models induced by DSS. Qi et al [99] set up rat colitis models induced by DSS and observed the anti-inflammatory effect of another GLP-2 analogue (polyethylene glycosylated porcine, GLP-2), the half-life of which is 16-fold longer that of the native GLP-2. This study confirmed that the GLP-2 analogue was able to lower the inflammation score in the affected colon and enhance the level of proinflammatory cytokines.…”

Section: Glp-2mentioning

confidence: 99%

A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System

Weigmann

2022

Metabolites

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a comprehensive term for chronic or relapsing inflammatory diseases occurring in the intestinal tract, generally including Crohn’s disease (CD) and ulcerative colitis (UC). Presently, the pathogenesis of IBD is unknown, yet multiple factors have been reported to be related with the development of IBD. Flavonoids are phytochemicals with biological activity, which are ubiquitously distributed in edible plants, such as fruits and vegetables. Recent studies have demonstrated impressively that flavonoids have anti-IBD effects through multiple mechanisms. These include anti-inflammatory and antioxidant actions; the preservation of the epithelial barrier integrity, the intestinal immunomodulatory property, and the shaping microbiota composition and function. In addition, a few studies have shown the impact of flavonoids on enterohormones release; nonetheless, there is hardly any work showing the link between flavonoids, enterohormones release and IBD. So far, the interaction between flavonoids, enterohormones and IBD is elucidated for the first time in this review. Furthermore, the inference can be drawn that flavonoids may protect against IBD through modulating enterohormones, such as glucagon-like peptide 1 (GLP-1), GLP-2, dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), ghrelin and cholecystokinin (CCK). In conclusion, this manuscript explores a possible mechanism of flavonoids protecting against IBD.

show abstract

Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats

Cited by 10 publications

References 30 publications

The Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Ameliorates Inflammatory Responses in DSS–Induced Ulcerative Colitis

The Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Ameliorates Inflammatory Responses in DSS–Induced Ulcerative Colitis

Quercetin: A Potential Drug Candidate for Inflammatory Bowel Disease

A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System

Contact Info

Product

Resources

About